Related Experiment Videos
Critical bleeding in surgery: conventional therapy and new prospects
1Department of Vascular Medicine/Internal Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. m.m.levi@amc.uva.nl
Minerva Anestesiologica
|June 8, 2004
Summary
This review explores prohemostatic agents to manage surgical bleeding. These agents enhance primary hemostasis, fibrin formation, or inhibit fibrinolysis, effectively reducing blood loss and transfusion needs.
Area of Science:
- Medical Science
- Surgical Complications
Background:
- Perioperative bleeding is a common surgical complication.
- Management involves local hemostasis, circulation support, and transfusions.
Purpose of the Study:
- To review agents with prohemostatic potential.
- To evaluate their efficacy in reducing perioperative blood loss.
Main Methods:
- Review of literature on prohemostatic agents.
- Discussion of mechanisms of action for desmopressin, recombinant activated factor VII, and anti-fibrinolytics (aprotinin, lysine analogues).
Main Results:
- Desmopressin augments primary hemostasis by increasing Von Willebrand factor.
- Recombinant activated factor VII targets the tissue factor/factor VIIa pathway.
- Anti-fibrinolytic agents (aprotinin, lysine analogues) inhibit fibrinolysis and protect platelets.
Conclusions:
- Prohemostatic therapy improves hemostasis through various mechanisms.
- These therapies are effective in reducing perioperative blood loss and transfusion requirements.